



DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 East William Street, Suite 101
Carson City, Nevada 89701
Telephone (775) 684-3676 • Fax (775) 687-3893
<http://dhcfp.nv.gov>

NOTICE OF PUBLIC MEETING – DRUG USE REVIEW BOARD

AGENDA

REVISED

Date of Posting: June 17, 2016

Date of Meeting: Thursday, July 28, 2016 at 5:15 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Drug Use Review Board (DUR).

Place of Meeting: Best Western Plus Airport Plaza Hotel
1981 Terminal Way
Reno, NV 89502
Phone: (775) 348-6370

Webinar Registration: Go to:
<https://catamaranrx.webex.com/catamaranrx/onstage/g.php?MTID=e7600cb1feb29ee4e0a1de879858d6df8>

Or go to www.webex.com and enter the Event Number listed below.

Once you have registered for the meeting, you will receive an email message confirming your registration. This message will provide the information that you need to join the meeting.

Event Number: 746 330 261

Click "Join Now"

Follow the instructions that appear on your screen to join the audio portion of the meeting. Audio will be transmitted over the internet. No phone number is required.

AGENDA

1. Call to Order and Roll Call

2. Public Comment on Any Matter on the Agenda

3. Administrative

- a. **For Possible Action:** Review and Approve Meeting Minutes from April 28, 2016.
- b. Status Update by DHCFP:
CMS final rule on covered outpatient drugs update.
Update on DUR Board policy changes from January and April.

4. Clinical Presentations

- a. **For Possible Action:** Discussion and possible adoption of prior authorization criteria for pediatric use of gonadotropin-releasing hormone (GnRH) analogs.
 - i. Public comment on adoption of policy.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by the Board and review of utilization data.
 - iv. Possible adoption of prior authorization criteria/policy.
- b. **For Possible Action:** Discussion and possible adoption of prior authorization criteria for medications used to treat Irritable-Bowel Syndrome.
 - i. Public comment on adoption of policy.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by the Board and review of utilization data.
 - iv. Possible adoption of prior authorization criteria/policy.
- c. **For Possible Action:** Discussion and possible removal of prior authorization criteria for duloxetine.
 - i. Public comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by the Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria.
- d. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria for the medication class Antiasthmatic Monoclonal Antibodies.

- i. Public Comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by the Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria
- e. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria for the medication class Hepatitis C Direct-acting antivirals.
 - i. Public comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria.
- f. **For Possible Action:** Discussion and possible adoption of prior authorization criteria and/or quantity limits for the medication class short-acting opioids and opioid agonists used for the treatment of pain.
 - i. Public comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria.

5. Public Comment on any DUR Board Requested Report

6. DUR Board Requested Reports

- a. Hepatitis C – 14 day trial compliance.
 - i. Discussion by the Board and review of utilization data.
- b. Long-acting steroid inhaler combination utilization correlated with emergency department visits and short-acting rescue medication utilization.
 - i. Discussion by the Board and review of utilization data.
- c. Utilization of short-acting insulin without long-acting/basal insulin.
 - i. Discussion by the Board and review of utilization data.
- d. Proton pump inhibitors and complications/adverse effects.
 - i. Discussion by the Board and review of utilization data.
- e. Long and short-acting opioid utilization.
 - i. Discussion by the Board and review of utilization data.

7. Public Comment on any Standard DUR Report

8. Standard DUR Reports

- a. Review of Prescribing/Program Trends.

- i. Top 10 Therapeutic Classes for Q4 2015, Q1 2016 and Q2 2016 (by Payment and by Claims).
 - ii. Top 50 Drugs of Q4 2015, Q1 2016 and Q2 2016 (by Payment and by Claims).
- b. Concurrent Drug Utilization Review (ProDUR)
 - i. Review of Q4 2015, Q1 2016 and Q2 2016.
 - ii. Review of Top Encounters by Problem Type.
- c. Retrospective Drug Utilization Review (RetroDUR)
 - i. Status of previous quarter.
 - ii. Status of current quarter.
 - iii. Review and discussion of responses.

9. Closing Discussion

- a. Public comments on any subject.
- b. Date and location of the next meeting.
 - i. Discussion of the time of the next meeting.
- c. Adjournment.

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to 5 minutes.

This notice and agenda have been posted at <http://dhcfp.nv.gov> and <http://notice.nv.gov> Carson City Central office and Las Vegas DHCFP. The agenda posting of this meeting can be viewed at the following locations: Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the meeting materials will be mailed to you. Requests and/or written comments may be sent to Ellen Felsing at the Division of Health Care Financing and

July 6, 2016

Page 5

Policy, 1100 E. William Street, Suite 101, Carson City, NV 89701, at least 3 days before the public hearing.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.

Note: We are pleased to make accommodations for members of the public who have disabilities and wish to attend the meeting. If special arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail at ellen.felsing@dhcfp.nv.gov in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Ellen Felsing at (775) 684-3684.